Colchicine-Binding Compounds for Drug-Resistant Cancer

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current cancer treatments, particularly those targeting microtubules, face challenges such as drug resistance and neurotoxicity, limiting their efficacy and safety.

Innovation Solution

Development of novel colchicine-binding site targeted compounds with improved aqueous solubility and the ability to circumvent P-glycoprotein-mediated multidrug resistance, potentially offering enhanced therapeutic effects while minimizing side effects.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If microtubule-targeting agents (taxanes, vinca alkaloids) are used to treat cancer, then cancer cell proliferation is inhibited, but drug resistance and neurotoxicity occur

Engineering Contradiction:

Improvecancer treatment efficacyVSAvoiddrug resistance and neurotoxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the binding site parameter from microtubule polymerization sites (taxanes) or vinca sites (vinca alkaloids) to the colchicine binding site on tubulin. This parameter change results in compounds that inhibit microtubule formation without the harmful effects of resistance and neurotoxicity associated with conventional agents.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent uses colchicine-site binding as an intermediary mechanism between the drug and tubulin. By binding at the colchicine site rather than directly stabilizing or destabilizing microtubules, the compound achieves cancer cell growth inhibition while avoiding the harmful effects of conventional microtubule-targeting agents.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If conventional microtubule-targeting drugs are administered, then cancer cells are targeted for treatment, but aqueous solubility is poor and toxicity increases

Engineering Contradiction:

Improvecancer treatment effectivenessVSAvoidtoxicity and poor solubility

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent modifies the pharmacological parameter of tubulin binding by targeting the colchicine site specifically. This changes the interaction mechanism to achieve both improved aqueous solubility and reduced toxicity while maintaining cancer treatment effectiveness.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

These compounds demonstrate potential in effectively treating cancer, including drug-resistant and metastatic forms, by inhibiting tubulin polymerization and inducing apoptosis in cancer cells, while showing improved safety profiles compared to existing microtubule-targeting agents.

Implementation Method 1

inhibiting tubulin polymerization and inducing apoptosis in cancer cells

Methodology Applied

Scientific EffectTubulin polymerization inhibition:

Implementation Method 2

inhibiting tubulin polymerization and inducing apoptosis in cancer cells

Methodology Applied

Scientific EffectApoptosis induction:

Data Source

PatentUS20250188072A1Compounds for treatment of cancer

Publication Date: 2025.06.12 UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION

AI summary

The present invention relates to novel compounds having anti-cancer activity, methods of making these compounds, and their use for treating cancer and drug-resistant tumors, e.g. melanoma, metastatic melanoma, drug resistant melanoma, prostate cancer and drug resistant prostate cancer.